Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OcuCure Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Tubulin is attracting increasing attention as a potential target to halt angiogenesis in the eye as well as in tumors. OcuCure Therapeutics Inc. is one of several firms developing it to treat macular degeneration. If this approach proves to be as effective as anti-VEGF approaches like Lucentis, OcuCure could be positioned to win over a significant share of the market as its drug would be administered topically, not via injection in the eye.
Advertisement

Related Content

Start-Up Previews (09/2007)
The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs
Start-Up Previews (09/2007)

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel